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Abstract
Background: It is well-known that nonsteroidal anti-inflammatory drugs (NSAIDs) can cause
damage to the small bowel associated with disruption of mucosal barrier function. In healthy human
volunteers, we showed previously that topical administration of adenosine 5'-triphosphate (ATP)
by naso-intestinal tube attenuated a rise in small intestinal permeability induced by short-term
challenge with the NSAID indomethacin. This finding suggested that ATP may be involved in the
preservation of intestinal barrier function. Our current objective was to corroborate the
favourable effect of ATP on indomethacin-induced permeability changes in healthy human
volunteers when ATP is administered via enteric-coated capsules, which is a more practically
feasible mode of administration. Since ATP effects may have been partly mediated through its
breakdown to adenosine, effects of encapsulated adenosine were tested also.
Methods: By ingesting a test drink containing 5 g lactulose and 0.5 g L-rhamnose followed by five-
hour collection of total urine, small intestinal permeability was assessed in 33 healthy human
volunteers by measuring the urinary lactulose/rhamnose excretion ratio. Urinary excretion of
lactulose and L-rhamnose was determined by fluorescent detection high-pressure liquid
chromatography (HPLC). Basal permeability of the small intestine was assessed as a control
condition (no indomethacin, no ATP/adenosine). As a model of increased small intestinal
permeability, two dosages of indomethacin were ingested at 10 h (75 mg) and 1 h (50 mg) before
ingesting the lactulose/rhamnose test drink. At 1.5 h before indomethacin ingestion, two dosages
of placebo, ATP (2 g per dosage) or adenosine (1 g per dosage) were administered via enteric-
coated hydroxypropyl methylcellulose (HPMC) capsules with Eudragit© L30D-55.
Results: Median urinary lactulose/rhamnose excretion ratio (g/g) in the control condition was
0.032 (interquartile range: 0.022–0.044). Compared to the control condition, lactulose/rhamnose
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ratio after ingestion of indomethacin plus placebo was significantly increased to 0.039 (0.035–
0.068); P < 0.01). The indomethacin-induced increase was neither affected by administration of
encapsulated ATP (0.047 (0.033–0.065)) nor adenosine (0.050 (0.030–0.067)). Differences in L/R
ratios between the conditions with indomethacin plus placebo, ATP or adenosine were not
significant.
Conclusion: In this study, either ATP or adenosine administered via enteric-coated capsules had
no effect on indomethacin-induced small intestinal permeability changes in healthy human
volunteers. The observed lack of effect of encapsulated ATP/adenosine may have been caused by
opening of the enteric-coated supplement at a site distal from the indomethacin-inflicted site.
Further studies on site-specific effectiveness of ATP/adenosine on intestinal permeability changes
are warranted.
Background
The intestinal mucosa on the luminal side of the gut is
continuously exposed to an immense load of antigens, for
instance from ingested food or resident bacteria. As a cru-
cial part of intestinal defence mechanisms, the mucosa is
involved in protecting the host against pathogenic sub-
stances. This protective function is called the intestinal
barrier function [1,2]. The mucosal enterocytes are of con-
siderable importance to this barrier function by control-
ling translocation of pathogenic substances.
In general, it has been proposed that there are two distinct
pathways in the intestine through which translocation
occurs, that is, a transcellular and a paracellular (i.e. inter-
cellular) pathway [3]. The functional integrity of the para-
cellular pathway can be assessed by measuring
gastrointestinal permeability with small saccharide mark-
ers. The use of a monosaccharide-disaccharide mixture
(such as rhamnose and lactulose) is particularly useful
since this provides information regarding villus tip 'dam-
age' as a function of villus surface area [4,5].
It has been shown that increased mucosal permeability of
the small intestine is associated with several gastrointesti-
nal disorders, including inflammatory bowel disease and
celiac disease [5,6]. In Crohn's disease, small intestinal
permeability is thought to be positively associated with
disease activity [7,8] and to be an early predictor of relapse
[9-12]. In addition to disease-related changes in intestinal
barrier function, several factors have been shown to nega-
tively affect intestinal permeability, including smoking
[13], alcohol intake [14,15] and use of nonsteroidal anti-
inflammatory drugs (NSAIDs) [16-18].
Frequent use of NSAIDs is associated with an elevated risk
of damage to the mucosal epithelium that lines the gas-
trointestinal tract lumen, thereby compromising integrity
of the mucosal barrier. One of the earliest events in
NSAID toxicity is uncoupling of oxidative phosphoryla-
tion within enterocytes resulting in depletion of cellular
energy stores in the form of adenosine 5'-triphosphate
(ATP), which leads to an increase in mucosal permeability
in the intestine [19]. It has been demonstrated in previous
experiments by Bjarnason and co-workers that mucosal
permeability of the small intestine is increased within 8–
10 hours after ingestion of two subsequent doses of the
NSAID indomethacin (75 and 50 mg); the permeability
increase is rapidly reverted, being no longer evident 48
hours after indomethacin ingestion [20-22]. Utilizing this
human model of increased intestinal permeability
induced by short-term challenge with indomethacin, we
recently showed that topical administration of ATP into
the upper small intestine attenuated the indomethacin-
induced increase in intestinal permeability in healthy
human volunteers [23]. In this randomized cross-over
study, fasting subjects received two subsequent indometh-
acin dosages (75 and 50 mg) concomitant with adminis-
tration of ATP or placebo directly into the upper small
intestine via a naso-intestinal tube. Intestinal permeabil-
ity was measured by the lactulose/rhamnose (L/R) sugar
absorption test, which is a widely used and sensitive per-
meability measure of the small intestine [24]. Results
showed that indomethacin induced an approximately
two-fold increase in median urinary L/R excretion ratio
relative to the basal L/R ratio in the control condition (i.e.
no indomethacin, no ATP). Administration of ATP con-
comitant with indomethacin ingestion completely pre-
vented the indomethacin-induced increase in L/R ratio
[23]. This finding suggested that ATP might be a beneficial
compound in alleviating detrimental NSAID effects in the
small intestine.
The aim of the present study was to confirm the favoura-
ble effect of ATP on the indomethacin-induced increase in
intestinal permeability, when ATP is administered via
enteric-coated capsules. In addition, since the effect of
ATP may have been partly mediated through its break-
down to adenosine, and since adenosine has well-known
anti-inflammatory and tissue-protective effects in the
intestine [25], we evaluated the effect of adenosine
administered via enteric-coated capsules in the sameBMC Gastroenterology 2007, 7:23 http://www.biomedcentral.com/1471-230X/7/23
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human model of indomethacin-induced permeability
changes in the small intestine.
Methods
Subjects
Non-smoking males and females between 18 and 30 years
of age were recruited for participation at Maastricht Uni-
versity, The Netherlands, by way of information pam-
phlets. Criteria for exclusion from participation, as
assessed by a short questionnaire, were: (1) history of gas-
trointestinal disease or current gastrointestinal disorder
(e.g. Crohn's disease, celiac disease), (2) current use of
NSAIDs (e.g. aspirin, ibuprofen), and (3) current use of
medication which could interfere with effects of ATP/ade-
nosine, including nucleoside transport inhibitors (e.g.
dipyridamole, lidoflazine), non-selective adenosine
receptor antagonists (e.g. theophylline, aminophylline),
xanthine oxidase inhibitors (e.g. allopurinol) and antide-
pressant drugs. All participants received oral and written
information about the aim and protocol of the study, and
gave their written informed consent before participation.
The study protocol was approved by the Ethics Committee
of Maastricht University, The Netherlands, and carried out
in compliance with the Helsinki Declaration.
Sample size
Sample size calculation for the present randomized cross-
over study was based on the results of our previous study
[23], in which subjects showed an average attenuation in
the indomethacin-induced increase in L/R ratio of 0.016
(i.e. a reduction of 33%) in response to topical ATP. In the
cross-over experiments of our previous study, a standard
deviation of 0.021 and correlation between paired meas-
ures of 0.74 were observed.
To be able to detect at least half of the previously observed
effect, that is ~15% reduction in L/R ratio, based on the
standard deviation of 0.021 and a correlation between
paired measures of 0.60 (i.e. a conservative estimate rela-
tive to the correlation of 0.74 observed in our previous
study), it was calculated that 31 subjects would be suffi-
cient to detect a significant effect of ATP/adenosine on an
indomethacin-induced increase in L/R ratio with a power
of 90% and two-tailed alpha of 0.05. Accounting for
potential dropout during experiments, a total of 35 partic-
ipants were recruited for the present study.
Protocol
The protocol of the present study was based on our previ-
ous study in which ATP was administered topically into
the upper small intestine via a naso-intestinal tube [23].
As a model of early-stage small intestinal enteropathy, a
number of experiments was performed; in each experi-
ment, two subsequent dosages of the NSAID indometh-
acin (75 and 50 mg) were administered to fasting healthy
human subjects. In a double-blind cross-over designed
study, each subject participated in four experiments, in a
randomized order and with wash-out periods of one week
in between: (1) control (no indomethacin, no ATP/ade-
nosine) as a measure of basal permeability of the small
intestine, (2) indomethacin + placebo, (3) indomethacin
+ ATP, and (4) indomethacin + adenosine.
Since alcohol intake is known to increase intestinal per-
meability to larger molecules (e.g. lactulose) [15], and
since caffeine is a non-selective adenosine receptor antag-
onist [26], participants were requested to abstain from
alcohol and caffeine-containing beverages or foods for
four days preceding and during each experiment. Also,
participants were asked not to perform any kind of pro-
longed strenuous physical exercise (e.g. long-distance run,
cycle race) during two days preceding each experiment,
since this has been shown to increase permeability of the
small intestine [27]. Antidepressants have been shown to
affect activity of the enzyme adenosine deaminase
[28,29], which catalyzes the breakdown of adenosine to
inosine. Current antidepressant use may therefore inter-
fere with effects of ATP/adenosine.
The control experiment comprised only the assessment of
basal permeability without any intervention: after an
overnight fast and after voiding, participants ingested a
test drink containing 5 g lactulose (Centrafarm Services
BV, Etten-Leur, The Netherlands) and 0.5 g L-rhamnose
(MP Biomedicals, Aurora, OH, USA) dissolved in 100 mL
water. Subsequently, total urine was collected for five
hours. During the last two hours of urine collection, sub-
jects were allowed unlimited intake of water, which stim-
ulates adequate urine production without influencing
urinary recovery of lactulose and L-rhamnose as well as
the lactulose/rhamnose excretion ratio [30]. Total urine
volume over the five-hour period was determined, and
urine aliquots were taken and stored at -80°C until anal-
ysis.
For the experiments with indomethacin plus placebo/
ATP/adenosine, at 11.5 h prior to the permeability assess-
ment (i.e. ingestion of the lactulose/rhamnose test drink),
participants ingested five capsules containing placebo, 2 g
ATP or 1 g adenosine. One and a half hour later, partici-
pants ingested 75 mg indomethacin (Genfarma, Zaan-
dam, The Netherlands). After an overnight fast, two and a
half hours before permeability assessment, participants
again ingested five capsules containing placebo, 2 g ATP
or 1 g adenosine, followed by a second dose of indometh-
acin (50 mg) at 1 h prior to the permeability assessment.
One hour later, after voiding, participants ingested the lac-
tulose/rhamnose test drink followed by collection of total
urine for five hours.BMC Gastroenterology 2007, 7:23 http://www.biomedcentral.com/1471-230X/7/23
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Experimental supplements
ATP, adenosine and placebo were administered via
enteric-coated hydroxypropyl methylcellulose (HPMC)
Vcaps capsules, which are two-piece capsules consisting of
a body and cap (a kind gift from the Laboratory of Phar-
maceutical Technology, Ghent University, Ghent, Bel-
gium). HPMC caps and bodies (capsule size 00: average
weight 118 mg, volume capacity 0.91 mL and closed
length 23.3 mm) were coated with Eudragit® L30D-55
[31]. The enteric coating of the HPMC capsules generally
dissolves within approximately 60 minutes after gastric
stage at pH 6.0 and within approximately 40 minutes at
pH 6.5, that is, in the proximal small intestine [31]. Using
an automatic capsule-filling machine (Blokland Medical
Supplies BV, IJsselstein, The Netherlands), the coated
bodies were filled with lactose (BUFA BV, Uitgeest, The
Netherlands), which was used as placebo as well as inert
excipient, and/or ATP or adenosine and closed with the
coated caps. Each participant ingested ATP by taking five
capsules twice, containing a dosage of 0.4 g ATP per cap-
sule, that is, 4 g ATP in total. Preliminary experiments
demonstrated the safety of this ATP dosage (H.J. Bos, P.C.
Dagnelie, unpublished observations). Adenosine was
administered at an equimolar dosage: each participant
ingested adenosine by taking five capsules twice, contain-
ing 0.2 g adenosine per capsule, that is, 2 g adenosine in
total. The dosage of lactose that was administered does
not produce symptoms of lactose intolerance, which are
reported to occur at dosages of about 12 to 18 g [32].
Intestinal permeability
Intestinal permeability was assessed using the lactulose/
rhamnose (L/R) sugar absorption test: ingestion of 5 g lac-
tulose and 0.5 g L-rhamnose dissolved in 100 mL water
followed by five-hour collection of total urine. This test is
based on the comparison of intestinal permeation of mol-
ecules of different sizes. The urinary L/R excretion ratio is
considered to be an accurate parameter of small intestinal
permeability [24]. Lactulose and L-rhamnose in collected
urine samples were determined by fluorescent detection
high-pressure liquid chromatography (HPLC). The
method for assaying lactulose and L-rhamnose has been
described previously [33]. In short, cellobiose was added
to urine samples as an internal standard, and the urine
was filtered through a 0.4-µm filter and diluted as neces-
sary. Samples were deionized and then injected onto a
Dionex MA-1 ion exchange column. Sugars were eluted
with NaOH at a flow rate of 0.4 mL/min with concentra-
tions ranging from 400 to 600 mmol/L. Peaks were
detected using pulsed amperometric detection on a
Dionex HPLC and quantified as peak areas. Calibration
was performed on a daily basis with authentic standards
at multiple concentrations, and the experimental stand-
ards were diluted so that the areas of all peaks fell within
the calibration range.
Statistics
Five-hour urinary excretion levels of lactulose and L-
rhamnose are presented as recovery (%) of ingested lactu-
lose and L-rhamnose, and as L/R ratios (g/g). Differences
in urinary L/R ratios between different conditions were
assessed using Wilcoxon signed ranks test. P-values below
0.05 were regarded statistically significant. Data are pre-
sented as Box-Whisker plots.
Results
For the present study, a total of 35 participants were
recruited, of whom two subjects did not complete all four
experiments. One subject had to stop after completion of
one experiment because of newly diagnosed celiac dis-
ease, and one subject only participated in two experi-
ments due to limitation of time. Thirty-three participants
(7 males, 26 females; age (mean ± SD) 22 ± 3.3 years;
range 18–30 years) completed all four experiments and
were included in the analyses. No side effects were
reported during the experiments.
Figure 1 shows L/R ratios of the four experimental condi-
tions. Median L/R ratio (g/g) in the control condition (no
indomethacin, no ATP/adenosine) was 0.032 (interquar-
tile range: 0.022–0.044). After ingestion of indomethacin
plus placebo, the median L/R ratio was significantly
increased to 0.039 (0.035–0.068; P < 0.01 vs. control).
Intake of enteric-coated capsules with either ATP or ade-
nosine at 1.5 h prior to indomethacin ingestion had no
effect on the indomethacin-induced increase in L/R ratio.
Median L/R ratio after ingestion of indomethacin plus
ATP was 0.047 (0.033–0.065; P = 0.22 vs. placebo), and
median L/R ratio after ingestion of indomethacin plus
adenosine was 0.050 (0.030–0.067; P = 0.49 vs. placebo).
Median L/R ratios after indomethacin ingestion with
administration of ATP or adenosine remained signifi-
cantly increased compared to the L/R ratio in the control
condition (P < 0.01, Fig. 1).
Table 1 shows total urine volumes (mL) and five-hour uri-
nary recovery (%) of orally ingested lactulose (5 g) and L-
rhamnose (0.5 g) in four experimental conditions. Five-
hour total urine volumes were similar in all experimental
conditions (Table 1). Compared to lactulose recovery in
the control condition (0.14% (0.08–0.22%)), urinary lac-
tulose recovery was significantly increased by ingestion of
indomethacin plus placebo (0.20% (0.11–0.31%); P <
0.01). Neither administration of ATP nor of adenosine
affected the indomethacin-induced increase in lactulose
permeation. Lactulose recovery after ingestion of capsules
with ATP was 0.18% (0.12–0.32%) and was 0.23% (0.11–
0.28%) after ingestion of capsules with adenosine; both
these values remained significantly increased compared to
the control condition (P < 0.01). Basal urinary recovery ofBMC Gastroenterology 2007, 7:23 http://www.biomedcentral.com/1471-230X/7/23
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L-rhamnose was not significantly affected by ingestion of
indomethacin plus placebo, ATP or adenosine (Table 1).
In all experimental conditions, no differences were found
between male and female subjects regarding urinary L/R
excretion ratios, total urine volumes and urinary recovery
of lactulose and L-rhamnose (data not shown).
Discussion
We previously reported that topical administration of ATP
into the human small intestine by naso-intestinal tube
attenuated an indomethacin-induced increase in mucosal
permeability in healthy human volunteers [23]. This find-
ing indicated that ATP administration may be of clinical
use by alleviating early adverse effects of NSAIDs and by
preserving small intestinal barrier function. Like in the
present study, early-phase small intestinal permeability
changes were induced by administering two subsequent
dosages of the NSAID indomethacin (75 and 50 mg).
Short-term indomethacin challenge causes a rapid (within
8–10 h) and temporary (< 48 h) increase in intestinal per-
meability, which can be assessed noninvasively by calcu-
lating the urinary excretion ratio of orally ingested
lactulose and L-rhamnose as markers of small intestinal
permeability [20-22,34]. 
To administer ATP experimentally in the upper small
intestine, the ATP in our previous study was administered
via a naso-intestinal tube. Since a naso-intestinal tube is a
useful way of administration in an experimental setting
but not in daily practice as it can cause great discomfort to
sensitive subjects or patients, the aim of the present study
was to corroborate the previously observed favourable
effect of ATP on indomethacin-induced permeability
changes when ATP was administered via enteric-coated
capsules, which is a more practically feasible mode of
administration. We also evaluated the effect of adenosine
administration via enteric-coated capsules, since we
hypothesized that the previously observed favourable
effect of ATP may have been partly mediated by its break-
down product adenosine, which has well-known anti-
inflammatory and tissue-protective properties in the
intestine [25].
Results of the present study show that, like in our previous
study, ingestion of two subsequent indomethacin dosages
significantly increases urinary L/R excretion ratio com-
pared to the L/R ratio in the control condition, which is a
measure of basal small intestinal permeability. The rise in
intestinal permeability was probably due to enhanced
permeation of lactulose, since urinary recovery of lactu-
lose, but not of rhamnose, was increased by indometh-
acin ingestion. Unexpectedly, neither administration of
encapsulated ATP nor adenosine affected the indometh-
acin-induced rise in small intestinal permeability, suggest-
ing that ATP and adenosine administered via enteric-
coated capsules are ineffective in attenuating an
indomethacin-induced increase in paracellular permea-
bility of the small intestinal mucosa in healthy humans.
Several potential explanations of the unexpected ineffec-
tiveness of both enteric-coated ATP and adenosine on
indomethacin-induced permeability changes in the
present study can be put forward. First, the possibility
should be considered that the present study results would
suggest a false-positive finding in our previous study,
meaning that the favourable effect of topically adminis-
tered ATP on small intestinal permeability changes
induced by indomethacin in our previous study was ran-
Box Whisker plot of urinary lactulose/rhamnose (L/R) excre- tion ratios (g/g) observed in four experimental conditions Figure 1
Box Whisker plot of urinary lactulose/rhamnose (L/R) excre-
tion ratios (g/g) observed in four experimental conditions. 
The control condition represents basal permeability of the 
small intestine, as indicated by the urinary L/R ratio after 
ingestion of a test drink containing 5 g lactulose and 0.5 g L-
rhamnose with no prior indomethacin ingestion and no pla-
cebo/ATP/adenosine challenge. The other conditions repre-
sent urinary L/R ratios after ingestion of two subsequent 
indomethacin dosages at 10 h (75 mg) and 1 h (50 mg) before 
ingestion of the test drink; at 1.5 h prior to the indomethacin 
dosages, two dosages of placebo (indomethacin + placebo), 
ATP (indomethacin + ATP, 2 g ATP per dosage) or adenos-
ine (indomethacin + adenosine, 1 g adenosine per dosage) 
were administered via enteric-coated capsules (*P < 0.01 vs. 
control; n = 33, Wilcoxon signed ranks test). Differences in 
L/R ratios between the conditions with indomethacin plus 
placebo, ATP or adenosine were not significant.BMC Gastroenterology 2007, 7:23 http://www.biomedcentral.com/1471-230X/7/23
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dom. However, the highly significant P-value (P < 0.01)
observed in our previous study, which was conducted
according to a double-blind, randomized cross-over
design, argues against the possibility of a false-positive
finding. Second, it could be argued that subject-related
differences between the present and our previous study
could be responsible for the different results. This expla-
nation is also unlikely since all study participants were
recruited from the same study base (i.e. students at Maas-
tricht University, The Netherlands), and age and sex ratio
of the participants were quite similar in both studies.
Moreover, permeability of the small intestinal mucosa of
healthy subjects, as assessed by urinary excretion ratio of
two different-sized test molecules, is thought to be inde-
pendent of age and gender [35,36]. Nevertheless, it must
be noted that intestinal permeability may vary considera-
bly under normal conditions, since basal permeability in
the present study appeared to be somewhat higher than in
our previous study (median L/R ratio of 0.032 vs. 0.023,
respectively) despite identical study design and methods.
A third possibility is that the ATP and adenosine within
the capsules were chemically unstable and therefore
degraded before application. However, this is unlikely
since capsules filled with ATP or adenosine in crystalline
form were stored dry at 4°C, at which storage conditions
both substances are stable for 24 months according to the
manufacturer's specifications (BUFA BV, Uitgeest, The
Netherlands). To confirm stability of the ATP used in the
present study, which had been stored at 4°C for several
months, we measured its quality by HPLC and found no
signs of any ATP degradation (data not shown). Also, the
enteric properties of the Eudragit© L30D-55 coating poly-
mer have been shown to be maintained even after 6
months of storage at different conditions [31]. A fourth
potential explanation of the ineffectiveness of ATP and
adenosine in the present study could be relative insolubil-
ity of ATP and adenosine. In our previous study, we
administered ATP as an aqueous solution (30 mg/kg ATP
dissolved in 100 mL water), whereas in the present study
ATP and adenosine were administered in crystalline form
within the enteric-coated HPMC capsules. However, since
both ATP and adenosine are substances which are freely
soluble in water [37], both are likely to dissolve within
minutes in the liquid environment of the gut upon open-
ing of the capsules. Finally, a possible explanation may be
a discrepancy between the intestinal site of indomethacin-
inflicted mucosal damage relative to the site of ATP/ade-
nosine delivery from the enteric-coated capsules in the
small intestine. It is believed that a short-term NSAID
challenge induces permeability changes mainly in the
upper small intestine (duodenum and proximal jejunum)
[38,39]. This would imply that the timing of the pH-
dependent release of ATP/adenosine by the enteric-coated
capsules might be an important factor limiting the effec-
tiveness of these compounds. In our previous study, in
which ATP was administered as an aqueous solution via a
naso-intestinal tube directly into the upper small intes-
tine, which is the intestinal site where indomethacin-
inflicted damage would occur, ATP attenuated the
indomethacin-induced increase in small intestinal perme-
ability [23]. In the present study, ATP and adenosine were
administered via HPMC capsules coated with Eudragit©
L30D-55 [31]. Huyghebaert et al. (2004) showed by in
vitro dissolution tests that the Eudragit© L30D-55 enteric-
coated capsules released 80% of their contents within 60
minutes at pH 6.0, with a lag-phase of 20 minutes after
simulated gastric stage. At pH 6.5, 80% of the capsule con-
tent was released within 30 minutes after simulated gastric
stage without lag-time [31]. In additional experiments by
our research group, in which lithium was used as a marker
to evaluate the timing of contents release by identical
enteric-coated capsules ingested by healthy subjects, we
observed rising lithium concentrations in plasma between
approximately 90 to 200 minutes following capsule inges-
tion, suggesting that opening of the capsules in vivo may
be subject to considerable variation (H.J. Bos, P.C. Dagne-
lie, unpublished observations). This would suggest that
the lack of effect of ATP and adenosine in the present
study might be explained by missing the target area of
indomethacin-inflicted upper-small-intestinal damage
Table 1: Five-hour total urine volumes (mL) and urinary recovery (%) of orally ingested lactulose (5 g) and L-rhamnose (0.5 g) in four 
experimental conditions (n = 33).
Experimental condition Recovery (%) 
Median (interquartile range)
Urine volume (mL) 
Median (interquartile range)
Lactulose Rhamnose
Control1 0.14 (0.08–0.22) 4.41 (3.31–5.88) 298 (182–613)
Indomethacin + placebo 0.20 (0.11–0.31)* 4.60 (3.15–5.91) 324 (193–493)
Indomethacin + ATP 0.18 (0.12–0.32)* 4.12 (3.23–4.89) 371 (165–518)
Indomethacin + adenosine 0.23 (0.11–0.28)* 4.52 (3.90–5.26) 307 (213–563)
1No indomethacin, no placebo/ATP/adenosine
Differences in lactulose/rhamnose recovery and urine volumes between the conditions with indomethacin plus placebo, ATP or adenosine were 
not significant
*P < 0.01 vs. control (Wilcoxon signed ranks test)BMC Gastroenterology 2007, 7:23 http://www.biomedcentral.com/1471-230X/7/23
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when administering ATP and adenosine via the Eudragit©
L30D-55 enteric-coated capsules.
Conclusion
In conclusion, we were not able to corroborate the previ-
ously shown beneficial effects of topical ATP administra-
tion on indomethacin-induced permeability changes in
the human small intestine, when using enteric-coated
capsules containing either ATP or adenosine as a more
practically feasible mode of administration. The most
likely explanation for the present finding is that the
enteric-coated supplement may have opened at an intesti-
nal site different (probably more distal) from the site
where mucosal damage by indomethacin occurs. Further
studies on site-specific effectiveness of encapsulated ATP
and adenosine on intestinal permeability changes are war-
ranted.
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